Esther Cw Breij

9PUBLICATIONS
58CO-AUTHORS
Molecular targetsHaematological tumoursSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 30, 2026
Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

|Oct 06, 2025
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Hilma J van der Horst, Tamás Csikós, Marjolein Quik

|Oct 13, 2023
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.

Jantine E Bakema, Marijke Stigter-van Walsum, Jeffrey R Harris

|Oct 22, 2022
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.

Kristel Kemper, Ellis Gielen, Peter Boross

|Feb 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Alexander Muik, Elena Garralda, Isil Altintas

|Feb 19, 2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.

Hilma J van der Horst, A Vera de Jonge, Ida H Hiemstra

Pageof 2

Frequent Collaborators

3 joint publications

Patrick J Engelberts

3 joint publications

Edward N van den Brink

3 joint publications

Dennis Verzijl

3 joint publications

Theo S Plantinga